Agilent Technologies Introduces Commercial Mouse Comparative Genomic Hybridisation Microarray
Agilent Technologies has introduced what the company claims to be the first commercial mouse Comparative Genomic Hybridisation (CGH) microarray. Designed and validated for genome-wide profiling of DNA copy number changes, the Agilent Mouse Genome GCH Microarray 44A offers a new venue and performance capability for studying genomic aberrations in cancer and other genetic diseases in this critical model organism.
"This technology is potentially transformative, as cross-species comparison can serve as a powerful biological filter for complex oncogenomic data from human cancers," said Lynda Chin, associate professor of dermatology at Dana-Farber Cancer Institute. "The availability of this microarray offers a new level of resolution and sensitivity in the genomic analyses of mouse tumours."
According to Agilent, the Mouse Genome CGH Microarray 44A provides comprehensive genome-wide coverage with an emphasis on the most commonly studied genomic regions and cancer-related genes. It consists of over 43,000 60-mer oligonucleotide probes, empirically validated in multiple model systems, that span coding and noncoding sequences with an average spatial resolution of 35 kb. Coupled with Agilent's CGH Analytics software, this microarray enables genome-wide survey and molecular profiling of genomic aberrations on a single chip.
This microarray joins the recently expanded Agilent oligo aCGH platform, which also includes reagents, hardware, software, and an improved assay protocol. Each experiment requires only nanogram levels of total genomic DNA without genome complexity reduction; and the HD-CGH custom microarrays for pinpointing chromosomal gains and losses associated with cancer and other genetic-based illnesses.
"We've taken extra measures to design a microarray that truly represents the coverage and performance needed to detect genomic gains and losses," said Mike Booth, general manager of Agilent's Genomics Business. "Along with human catalogue and custom HD-CGH microarrays, it gives researchers access to the most robust and complete family of application-specific products."
Comments